Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00609011 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma
A Phase 1 study, sponsored by Myrexis.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00609011: Completed Phase 1 study, sponsored by Myrexis.
NCT00609011 is a Phase 1 study that has completed, run by Myrexis. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00609011, a Phase 1 study, has completed, sponsored by Myrexis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is an open-label, dose finding, multiple-dose study in subjects with metastatic melanoma. Three dose levels of MPC-6827 will be administered with temozolomide to three separate cohorts. Study endpoints will include determination of the maximum tolerated dose, determination of dose limiting toxicities, and evaluation of evidence of anti-tumor activity of MPC-6827 when given with temozolomide.
Interventions
- DRUG MPC-6827 + Temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2008-03 |
| Est. Completion | 2009-08 |
| Phase | Phase 1 |
What the finished NCT00609011 record still lists
NCT00609011 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 1 intervention - of which MPC-6827 + Temozolomide is the first listed.
NCT00609011 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00609011 about?
NCT00609011 is a clinical study titled "Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma". This is an open-label, dose finding, multiple-dose study in subjects with metastatic melanoma. Three dose levels of MPC-6827 will be administered with temozolomide to three separate cohorts. Study endpoints will include determination of the maximum tolerated dose, determination of dose limiting toxi...
What is the current status of trial NCT00609011?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2008-03. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00609011?
The interventions under investigation include: MPC-6827 + Temozolomide (DRUG).
Who is sponsoring clinical trial NCT00609011?
This trial is sponsored by Myrexis, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00609011's enrollment target sits among peer trials
22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia